tradingkey.logo

Neurosense Therapeutics Ltd

NRSN
0.940USD
+0.070+8.03%
Handelsschluss 02/06, 16:00ETKurse um 15 Minuten verzögert
23.12MMarktkapitalisierung
VerlustKGV TTM

Neurosense Therapeutics Ltd

0.940
+0.070+8.03%

mehr Informationen über Neurosense Therapeutics Ltd Unternehmen

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Neurosense Therapeutics Ltd Informationen

BörsenkürzelNRSN
Name des UnternehmensNeurosense Therapeutics Ltd
IPO-datumDec 09, 2021
CEOBen-Noon (Alon)
Anzahl der mitarbeiter15
WertpapierartOrdinary Share
GeschäftsjahresendeDec 09
Addresse11 Hamenofim St.
StadtHERZLIYA
BörseNASDAQ OMX - NASDAQ BASIC
LandIsrael
Postleitzahl4672562
Telefon97297996183
Websitehttps://www.neurosense-tx.com/
BörsenkürzelNRSN
IPO-datumDec 09, 2021
CEOBen-Noon (Alon)

Führungskräfte von Neurosense Therapeutics Ltd

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
3.18M
+93666.00%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
480.92K
+20916.00%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
189.62K
+66667.00%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
64.00K
--
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
24.00K
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Revital Mandil-Levin, Ph.D.
Dr. Revital Mandil-Levin, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
3.18M
+93666.00%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
480.92K
+20916.00%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
189.62K
+66667.00%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
64.00K
--
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
24.00K
--
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sat, Jan 31
Aktualisiert: Sat, Jan 31
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Ben-Noon (Alon)
10.69%
Rimon Gold Assets Ltd
7.76%
Eisenberg (Or)
1.62%
Tracik (Ferenc)
0.64%
Squarepoint Capital LLP
0.32%
Andere
78.97%
Aktionäre
Aktionäre
Anteil
Ben-Noon (Alon)
10.69%
Rimon Gold Assets Ltd
7.76%
Eisenberg (Or)
1.62%
Tracik (Ferenc)
0.64%
Squarepoint Capital LLP
0.32%
Andere
78.97%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
13.78%
Corporation
7.76%
Investment Advisor/Hedge Fund
0.37%
Investment Advisor
0.35%
Research Firm
0.15%
Hedge Fund
0.07%
Bank and Trust
0.05%
Andere
77.47%

Institutionelle Beteiligung

Aktualisiert: Thu, Jan 1
Aktualisiert: Thu, Jan 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
30
293.14K
0.99%
-2.10M
2025Q3
29
437.13K
1.75%
-1.60M
2025Q2
37
7.64M
31.03%
+143.76K
2025Q1
39
7.45M
37.28%
+353.50K
2024Q4
38
7.90M
34.02%
+1.29M
2024Q3
32
5.18M
22.45%
-1.31M
2024Q2
35
6.62M
30.57%
+1.57M
2024Q1
38
5.18M
33.20%
-953.28K
2023Q4
38
5.12M
32.81%
-1.05M
2023Q3
33
5.76M
47.99%
-945.27K
Mehr Anzeigen

Aktionärsaktivitäten

Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Ben-Noon (Alon)
3.18M
10.69%
+93.67K
+3.04%
Apr 07, 2025
Rimon Gold Assets Ltd
2.30M
7.76%
+2.30M
--
Dec 02, 2024
Eisenberg (Or)
480.92K
1.62%
+20.92K
+4.55%
Apr 07, 2025
Tracik (Ferenc)
189.62K
0.64%
+66.67K
+54.22%
Apr 07, 2025
Squarepoint Capital LLP
95.38K
0.32%
+45.45K
+91.04%
Sep 30, 2025
Russek-Blum (Niva)
75.43K
0.25%
+10.00K
+15.28%
Apr 07, 2025
Leuchtenberger (Mark W)
64.00K
0.22%
--
--
Apr 07, 2025
Morgan Stanley & Co. LLC
41.40K
0.14%
-38.50K
-48.19%
Sep 30, 2025
Meitav Investment House Ltd
40.00K
0.13%
--
--
Sep 30, 2025
Binder (Hagit)
32.00K
0.11%
+10.00K
+45.45%
Apr 07, 2025
Mehr Anzeigen

Verbundene ETFs

Name
Anteil
Keine Daten

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten

Aktien-Split

Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
KeyAI